BridgeBio Pharma (FRA:2CL) Dividends per Share : €0.00 (TTM As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Dividends per Share?

BridgeBio Pharma's dividends per share for the three months ended in Jun. 2024 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00. Its Dividend Payout Ratio for the three months ended in Jun. 2024 was 0.00. As of today, BridgeBio Pharma's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

BridgeBio Pharma Dividends per Share Historical Data

The historical data trend for BridgeBio Pharma's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Dividends per Share Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Get a 7-Day Free Trial

BridgeBio Pharma Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BridgeBio Pharma's Dividends per Share

For the Biotechnology subindustry, BridgeBio Pharma's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Pharma's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's Dividend Yield % falls into.

BridgeBio Pharma Dividends per Share Calculation

Dividends paid to per common share.

BridgeBio Pharma (FRA:2CL) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

BridgeBio Pharma's Dividend Payout Ratio for the quarter that ended in Jun. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2024 )	/	EPS without NRI (Q: Jun. 2024 )
	=	0	/	-0.968
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

BridgeBio Pharma Dividends per Share Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

BBIO:USA

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

BridgeBio Pharma Headlines

No Headlines